Tolerance of antiretroviral drugs during pregnancy;Tolérance pour l'enfant des antirétroviraux durant la grossesse

Medecine/Sciences

Volumn 29, Issue 4, 2013, Pages 383-388

  Blanche, Stéphane ^a   Warszawski, Josiane ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MITOCHONDRIAL DNA; MUTAGENIC AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHEMICALLY INDUCED DISORDER; CONGENITAL MALFORMATION; DISEASE TRANSMISSION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PREMATURITY; VERTICAL TRANSMISSION;

ABNORMALITIES, DRUG-INDUCED; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; DNA, MITOCHONDRIAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MUTAGENS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84876941001     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/2013294011     Document Type: Article

References (35)

1. Lallemant M, Jourdain G, Le Coeur S, et al. Prévention de la transmission mère-enfant du VIH : un protocole simple, d'une efficacité remarquable. Med Sci (Paris) 2005 ; 21 : 28-9.
2. Heidari S, Mofenson L, Cotton MF, et al. Antiretroviral drugs for preventing mother-to-child transmission of HIV: A review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr 2011 ; 57 : 290-6.
3. Mahy M, Stover J, Kiragu K, et al. What will it take to achieve virtual elimination of mother-to-child transmission of HIV? An assessment of current progress and future needs. Sex Transm Infect 2010 ; 86 Suppl 2 : ii48-55.
4. Antiretroviral drugs for treating women and preventing HIV infection in infants. WHO guidelines. http://www.who.int/hiv; accessed 20 April 2012.
5. Watts DH, Williams PL, Kacanek D, et al. Pediatric HIV/AIDS Cohort Study. Combination antiretroviral use and preterm birth. J Infect Dis 2013 ; 207 : 612-21.
6. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis 2012 ; 54 : 1348-60.
7. Warszawski J, Le Chenadec J, Mandelbrot L, et al. and the French Perinatal Cohort (ANRS CO1/CO11). Infant mortality among HIV-uninfected children during the HAART Era in France - The ANRS French perinatal cohort. Poster no 1032 presented at the 19th CROI, Seattle 2012.
8. Chou R, Cantor A, Bougatsos C, Zakher B. Screening for HIV in pregnant women: systematic review to update the U.S. preventive services task force recommendation. Rockville (MD): Agency for healthcare research and quality (US), 2012. Available from http://www.ncbi.nlm.nih.gov/books/ NBK114880.
9. http://whqlibdoc.who.int/publications/2012/9789241503792-eng.pdf
10. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011 ; 25 : 2301-4.
11. Knapp KM, Brogly SB, Muenz DG, et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 2012 ; 31 : 164-70.
12. Sibiude J, Mandelbrot L, Blanche S, et al. Birth defects and antiretroviral therapy: Zidovudine in the first trimester is associated to congenital heart defects in the EPF French perinatal xohort. JAMA 2013 (sous presse).
13. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS clinical trials group protocol 076 study group. N Engl J Med 1994 ; 331 : 1173-80.
14. Crain MJ, Williams PL, Griner R, et al. Pediatric HIVAIDS Cohort Study. Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications. Pediatr Infect Dis J 2011 ; 30 : 1069-74.
15. Blanche S. Mitochondrial dysfunction following perinatal exposure to nucleoside analogues AIDS 2006 ; 20 : 1685-90.
16. Divi RL, Leonard SL, Kuo MM, et al. Cardiac mitochondrial compromise in one year old Erythrocebus patas monkeys exposed in utero to nucleoside reverse transcriptase inhibitors. Cardiovasc Toxicol 2005 ; 5 : 333-46.
17. Dauby N, Goetghebuer T, Kollmann TR, et al. Uninfected but not unaffected: chronic maternal infections during pregnancy, fetal immunity, and susceptibility to postnatal infections. Lancet Infect Dis 2012 ; 12 : 330-40.
18. Ross AC, Leong T, Avery A, et al. Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress. HIV Med 2012 ; 13 : 98-106.
19. Simon A, Warszawski J, Kariyawasam D, et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 2011 ; 306 : 70-8.
20. http://www.fda;gov/Safety/Med Watch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm246167.htm.
21. Olivero OA, Shearer GM, Chougnet CA, et al. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS 1999 ; 13 : 919-25.
22. Escobar PA, Olivero OA, Wade NA, et al. Genotoxicity assessed by the comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC. Environ Mol Mutagen 2007 ; 48 : 330-43.
23. Witt KL, Cunningham CK, Patterson KB, et al. Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. Environ Mol Mutagen 2007 ; 48 : 322-9.
24. Senda S, Blanche S, Costagliola D, et al. Altered heterochromatin organization after perinatal exposure to zidovudine. Antivir Ther 2007 ; 12 : 179-87.
25. Olivero OA. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 2007 ; 48 : 215-23.
26. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999 ; 354 : 1084-9.
27. Brogly SB, DiMauro S, Van Dyke RB, et al. Transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected children. AIDS Res Hum Retroviruses 2011 ; 27 : 777-83.
28. Lipshultz SE, Shearer WT, Thompson B, et al. Cardiac effects of antiretroviral therapy in HIVnegative infants born to HIV-positive mothers: The NHLBI CHAART-1 cohort study. J Am Coll Cardiol 2011 ; 57 : 76-85.
29. Cade WT, Waggoner AD, Hubert S, et al. Reduced diastolic function and left ventricular mass in HIV-negative pre-adolescent children exposed to antiretroviral therapy in utero. AIDS 2012 ; 26 : 2053-8.
30. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S. Enqun̂te périnatale française study group. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003 ; 17 : 2053-61.
31. Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the women and infants transmission study. J Infec Dis 2006 ; 194 : 1089-97.
32. Bunders MJ, Bekker V, Scherpbier HJ, et al. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr 2005 ; 94 : 1571-7.
33. Andre-Schmutz I, Dal-Cortivo L, Six E, et al. Genotoxic signature in cord blood cells of newborns exposed in utero to a zidovudine-based antiretroviral combination. J Inf Dis 2013 ; sous presse.
34. Olivero O, Torres LR, Gorjifard S, et al. Perinatal exposure of patas monkeys to antiretroviral nucleoside reverse transcriptase inhibitors induces genotoxicity persistent for up to 3 years of age. J Infect Dis 2013 ; sous presse.
35. Benhammou V, Warszawski J, Bellec S, et al. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors. AIDS 2008 ; 22 : 2165-77.